Medtronic plc

Medtronic is a global medical-technology giant across cardiovascular, neuroscience, medical-surgical and diabetes categories. It's a slow, steady compounder that has quietly done nothing over the last twelve months as growth persisted but the multiple stayed skeptical — with earnings dropping tomorrow (Sept 1) as the specific catalyst for the tape.

• The operating cadence is unglamorous but consistent: quarterly revenue growth ran 6.6-9.9% year-over-year across the last four quarters, gross margins hold in the 58-76% range, and the last four EPS prints beat consensus by 0.6-3.8% — a blue chip with no growth theatrics but no misses either.
• The valuation is fair rather than cheap: at 22x trailing earnings with a 5.1% free-cash-flow yield, this is priced as a boring mega-cap medtech — the Mizuho $100 base-case (13.5x EV/EBITDA and 16x P/E) is essentially the market's own default view, and any positive Q1 print reads as multiple expansion.
• The specific FY27 drivers are named: Hugo (surgical robotics) is Medtronic's answer to Intuitive's da Vinci franchise, and Renal Denervation (RDN) is the hypertension-device business finally scaling — both are real revenue lines analysts underwrite into the FY27 EPS trajectory of $5.95.
• Insider action is comp-related but large in dollar terms: CEO Geoffrey Martha received a $49M A-Award grant, and other officers received $6-7M performance grants Aug 4 — those are compensation-cycle events, not open-market signals, but they anchor management incentives to price targets well above spot.

The path if it works is the Sept 1 print beating on both Hugo unit placements and RDN commercial adoption — the tape reprices from stall to a re-rate toward the $100 area many are targeting. What breaks the setup is a soft Q1 with a rebased guide or Hugo unit-placement miss; that's when a blue chip trading at 22x earnings gives back to the 20x support many hold at, and the year-flat tape becomes a year-negative one.